{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:17:23Z","timestamp":1777396643228,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2023,12,6]]},"abstract":"<jats:p>Background: The agrammatic variant of primary progressive aphasia (PAA), primary progressive apraxia of speech (PPAOS), or a combination of both (AOS-PAA) are neurodegenerative disorders characterized by speech-language impairments and together compose the AOS-PAA spectrum disorders. These patients typically have an underlying 4-repeat tauopathy, although they sometimes show evidence of amyloid-\u03b2 and tau deposition on PET, suggesting Alzheimer\u2019s disease (AD). Given the growing number of pharmacologic treatment options for AD, it is important to better understand the incidence of AD pathology in these patients. Objective: This study aimed to evaluate the frequency of amyloid-\u03b2 and tau positivity in AOS-PAA spectrum disorders. Sixty-five patients with AOS-PAA underwent a clinical speech-language battery and PiB PET and flortaucipir PET imaging. Methods: Global PiB PET standardized uptake value ratios (SUVRs) and flortaucipir PET SUVRs from the temporal meta region of interest were compared between patient groups. For 19 patients who had died and undergone autopsy, their PET and pathology findings were also compared. Results: The results showed that although roughly half of the patients are positive for at least one biomarker, their clinical symptoms and biomarker status were not related, suggesting that AD is not the primary cause of their neurodegeneration. All but one patient in the autopsy subset had a Braak stage of IV or less, despite four being positive on tau PET imaging. Conclusions: Inclusion criteria for clinical trials should specify clinical presentation or adjust the evaluation of such treatments to be specific to disease diagnosis beyond the presence of certain imaging biomarkers.<\/jats:p>","DOI":"10.3233\/jad-230912","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T11:35:12Z","timestamp":1700566512000},"page":"1759-1765","source":"Crossref","is-referenced-by-count":2,"title":["Amyloid and Tau PET Positivity in Progressive Agrammatic Aphasia and Apraxia of Speech"],"prefix":"10.1177","volume":"96","author":[{"given":"Katerina A.","family":"Tetzloff","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nha Trang Thu","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"Machulda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Botha","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Josephs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene L.","family":"Utianski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-230912_ref1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"10.3233\/JAD-230912_ref2","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/brain\/awl078","article-title":"Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech","volume":"129","author":"Josephs","year":"2006","journal-title":"Brain"},{"key":"10.3233\/JAD-230912_ref3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/jnnp-2013-306948","article-title":"New criteria for frontotemporal dementia syndromes: Clinical and pathological diagnostic implications","volume":"85","author":"Chare","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-230912_ref4","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1212\/01.wnl.0000436070.28137.7b","article-title":"Classification and pathology of primary progressive aphasia","volume":"81","author":"Harris","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-230912_ref5","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-021-23687-8","article-title":"A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech","volume":"12","author":"Josephs","year":"2021","journal-title":"Nat Commun"},{"key":"10.3233\/JAD-230912_ref6","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1093\/brain\/awr216","article-title":"Subtypes of progressive aphasia: Application of the International Consensus Criteria and validation using \u03b2-amyloid imaging","volume":"134","author":"Leyton","year":"2011","journal-title":"Brain"},{"key":"10.3233\/JAD-230912_ref7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaneurol.2017.4309","article-title":"Rates of amyloid imaging positivity in patients with primary progressive aphasia","volume":"75","author":"Santos-Santos","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230912_ref8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jalz.2014.03.004","article-title":"APOE \u025b4 influences \u03b2-amyloid deposition in primary progressive aphasia and speech apraxia","volume":"10","author":"Josephs","year":"2014","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230912_ref9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.nicl.2016.01.014","article-title":"Clinical and MRI models predicting amyloid deposition in progressive aphasia and apraxia of speech","volume":"11","author":"Whitwell","year":"2016","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-230912_ref10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1044\/2022_AJSLP-22-00148","article-title":"The apraxia of speech rating scale: Reliability, validity, and utility","volume":"32","author":"Duffy","year":"2023","journal-title":"Am J Speech Lang Pathol"},{"key":"10.3233\/JAD-230912_ref11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcomdis.2014.06.008","article-title":"The Apraxia of Speech Rating Scale: A tool for diagnosis and description of apraxia of speech","volume":"51","author":"Strand","year":"2014","journal-title":"J Commun Disord"},{"key":"10.3233\/JAD-230912_ref12","doi-asserted-by":"crossref","unstructured":"Kertesz A (2007) Western Aphasia Battery\u2013Revised.","DOI":"10.1037\/t15168-000"},{"key":"10.3233\/JAD-230912_ref13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/arclin\/14.6.481","article-title":"An empirically derived short form of the Boston naming test","volume":"14","author":"Lansing","year":"1999","journal-title":"Arch Clin Neuropsychol"},{"key":"10.3233\/JAD-230912_ref14","unstructured":"Warrington EK (1996) The Camden memory tests manual, Psychology Press."},{"key":"10.3233\/JAD-230912_ref15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","article-title":"Prevalence of biologically vs clinically defined alzheimer spectrum entities using the National Institute on Aging-Alzheimer\u2019s Association Research Framework","volume":"76","author":"Jack","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-230912_ref16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230912_ref17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","article-title":"The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease","volume":"41","author":"Mirra","year":"1991","journal-title":"Neurology"},{"key":"10.3233\/JAD-230912_ref18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-230912_ref19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JAD-230912_ref20","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1001\/archneur.61.10.1579","article-title":"Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration","volume":"61","author":"Josephs","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-230912_ref21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease","volume":"8","author":"Hyman","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230912_ref22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","article-title":"Tau-positron emission tomography correlates with neuropathology findings","volume":"16","author":"Lowe","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230912_ref23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ana.25893","article-title":"Sensitivity-specificity of tau and amyloid \u03b2 positron emission tomography in frontotemporal lobar degeneration","volume":"88","author":"Ghirelli","year":"2020","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-230912_ref24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.3233\/JAD-230912_ref25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nicl.2017.09.016","article-title":"Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer\u2019s disease","volume":"17","author":"Iaccarino","year":"2018","journal-title":"Neuroimage Clin"},{"key":"10.3233\/JAD-230912_ref26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/hbm.24473","article-title":"Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer\u2019s disease","volume":"40","author":"Sintini","year":"2019","journal-title":"Hum Brain Mapp"},{"key":"10.3233\/JAD-230912_ref27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","article-title":"Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer\u2019s disease","volume":"14","author":"Whitwell","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-230912_ref28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e31829c5ed5","article-title":"Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA","volume":"81","author":"Josephs","year":"2013","journal-title":"Neurology"},{"key":"10.3233\/JAD-230912_ref29","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/brain\/aws032","article-title":"Characterizing a neurodegenerative syndrome: Primary progressive apraxia of speech","volume":"135","author":"Josephs","year":"2012","journal-title":"Brain"},{"key":"10.3233\/JAD-230912_ref30","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/brain\/awz157","article-title":"Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome","volume":"142","author":"Tetzloff","year":"2019","journal-title":"Brain"},{"key":"10.3233\/JAD-230912_ref31","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cortex.2017.12.021","article-title":"Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech","volume":"99","author":"Utianski","year":"2018","journal-title":"Cortex"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-230912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:57Z","timestamp":1777370937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-230912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":31,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-230912","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]}}}